A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
MESA LABORATORIES INC /CO/
MLAB
$535M
Mkt Cap
$97.50
-3.42%
MESA LABORATORIES INC /CO/ (MLAB) has a current P/E ratio of 150.0, compared to its historical median P/E of 35.4. The stock is currently considered Expensive based on its historical valuation range.
MESA LABORATORIES INC /CO/ (MLAB) has a 5-year average return on invested capital (ROIC) of -11.8%. This is below average and may indicate limited pricing power.
MESA LABORATORIES INC /CO/ (MLAB) has a market capitalization of $539M. It is classified as a small-cap stock.
Yes, MESA LABORATORIES INC /CO/ (MLAB) pays a dividend with a trailing twelve-month yield of 0.65%.
Based on historical P/E analysis, MESA LABORATORIES INC /CO/ (MLAB) appears expensive. The current P/E of 150.0 is 324% above its historical median of 35.4. The estimated fair value CAGR (P/E method) is -27.7%.
MESA LABORATORIES INC /CO/ (MLAB) operates in the Industrial Instruments For Measurement, Display, And Control industry, within the Technology sector.
MESA LABORATORIES INC /CO/ (MLAB) reported annual revenue of $241 million in its most recent fiscal year, based on SEC EDGAR filings.
In this Annual Report on Form 10-K, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries is collectively referred to as “we,” “us,” “our,” the “Company,” or "Mesa." Mesa was organized in 1982 as a Colorado corporation. We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 248M | 241M | 216M | 219M | 184M | 134M |
| Net Income | 3.7M | -2.0M | -254M | 930K | 1.9M | 3.3M |
| EPS | $0.65 | $-0.36 | $-47.20 | $0.17 | $0.35 | $0.64 |
| Free Cash Flow | 38M | 43M | 42M | 23M | 35M | 35M |
| ROIC | 2.3% | 4.1% | -71.7% | 0.6% | 0.7% | 7.4% |
| Gross Margin | 62.4% | 62.6% | 61.6% | 61.0% | 59.2% | 65.0% |
| Debt/Equity | 0.39 | 1.12 | 0.35 | 0.47 | 0.55 | 0.36 |
| Dividends/Share | $0.64 | $0.64 | $0.64 | $0.64 | $0.64 | $0.64 |
| Operating Income | 17M | 16M | -272M | 3.3M | 4.7M | 12M |
| Operating Margin | 7.0% | 6.8% | -125.9% | 1.5% | 2.6% | 9.2% |
| ROE | 2.0% | -1.3% | -94.4% | 0.2% | 0.5% | 1.0% |
| Shares Outstanding | 6M | 5M | 5M | 5M | 5M | 5M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 53M | 71M | 85M | 94M | 96M | 103M | 118M | 134M | 184M | 219M | 216M | 241M | 248M |
| Gross Margin | 60.1% | 60.8% | 60.7% | 56.8% | 56.8% | 59.1% | 55.5% | 65.0% | 59.2% | 61.0% | 61.6% | 62.6% | 62.4% |
| R&D | 2.3M | 3.3M | 4.0M | 4.2M | 3.5M | 3.5M | 6.4M | 10M | 16M | 20M | 19M | 20M | 20M |
| SG&A | 11M | 17M | 24M | 23M | 26M | 31M | 38M | 46M | 60M | 72M | 73M | 73M | 75M |
| EBIT | 12M | 16M | 16M | 16M | 2.2M | 9.8M | 7.9M | 12M | 4.7M | 3.3M | -272M | 16M | 17M |
| Op. Margin | 22.4% | 22.2% | 19.3% | 17.4% | 2.3% | 9.5% | 6.7% | 9.2% | 2.6% | 1.5% | -125.9% | 6.8% | 7.0% |
| Net Income | 9.0M | 9.6M | 11M | 11M | -3.0M | 7.5M | 1.8M | 3.3M | 1.9M | 930K | -254M | -2.0M | 3.7M |
| Net Margin | 17.1% | 13.4% | 13.2% | 11.9% | -3.1% | 7.3% | 1.5% | 2.4% | 1.0% | 0.4% | -117.6% | -0.8% | 1.5% |
| Non-Recurring | 420K | -16K | 0 | 0 | 14M | 1.4M | 224K | 0 | 0 | 0 | 157M | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | 12.6% | 10.3% | 9.7% | 9.5% | 0.9% | 6.5% | 2.8% | 7.4% | 0.7% | 0.6% | -71.7% | 4.1% | 2.3% |
| ROE | 15.4% | 13.9% | 14.1% | 12.3% | -3.0% | 7.1% | 1.1% | 1.0% | 0.5% | 0.2% | -94.4% | -1.3% | 2.0% |
| ROA | 11.0% | 8.9% | 8.0% | 6.7% | -1.8% | 4.7% | 0.6% | 0.6% | 0.3% | 0.1% | -45.9% | -0.4% | 0.9% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 12M | 11M | 17M | 17M | 26M | 31M | 27M | 37M | 39M | 28M | 44M | 47M | 42M |
| Free Cash Flow | 11M | 8.0M | 9.2M | 5.7M | 23M | 29M | 25M | 35M | 35M | 23M | 42M | 43M | 38M |
| Owner Earnings | 7.7M | 4.2M | 8.4M | 7.2M | 15M | 17M | 8.5M | 10M | 2.8M | -18M | 623K | 9.1M | 23M |
| CapEx | 1.0M | 2.8M | 7.7M | 12M | 2.8M | 1.3M | 1.5M | 2.0M | 4.4M | 4.5M | 2.6M | 4.2M | 3.6M |
| Maint. CapEx | 3.8M | 5.7M | 7.2M | 8.7M | 9.5M | 9.4M | 13M | 18M | 25M | 34M | 32M | 25M | 4.4M |
| Growth CapEx | 0 | 0 | 555K | 2.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 3.8M | 5.7M | 7.2M | 8.7M | 9.5M | 9.4M | 13M | 18M | 25M | 34M | 32M | 25M | 4.4M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 4.1% | 5.6% | 5.4% | 11.3% | 16.2% | 5.8% | 9.1% | 8.6% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 2.0M | 2.2M | 2.3M | 2.4M | 2.4M | 2.5M | 2.7M | 3.2M | 3.3M | 3.4M | 3.4M | 3.5M | 3.5M |
| Dividend Yield | 0.9% | 0.8% | 0.7% | 0.5% | 0.5% | 0.3% | 0.3% | 0.2% | 0.2% | 0.3% | 0.5% | 0.5% | 0.7% |
| Share Buybacks | 22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 840K | 993K | 1.3M | 1.4M | 1.7M | 4.2M | 5.5M | 9.3M | 11M | 13M | 12M | 13M | 14M |
| Debt Repayment | 8.5M | 13M | 6.0M | 57M | 20M | 26M | 23M | 0 | 21M | 36M | 34M | 44M | 44M |
| Balance Sheet | |||||||||||||
| Net Debt | 11M | 41M | 40M | 49M | 41M | 13M | -7.8M | -349M | 169M | 150M | 22M | 151M | 15M |
| Cash & Equiv. | 5.6M | 2.0M | 5.7M | 5.8M | 5.5M | 10M | 81M | 264M | 49M | 33M | 28M | 27M | 58M |
| Long-Term Debt | 17M | 23M | 42M | 54M | 45M | 21M | 140M | 146M | 169M | 170M | 0 | 71M | 63M |
| Debt/Equity | 0.26 | 0.58 | 0.53 | 0.56 | 0.47 | 0.20 | 0.64 | 0.36 | 0.55 | 0.47 | 0.35 | 1.12 | 0.39 |
| Interest Coverage | 88.6 | 31.8 | 19.2 | 36.3 | 1.2 | 5.6 | 1.4 | 1.5 | 1.2 | 0.7 | -47.8 | 1.4 | 1.6 |
| Equity | 64M | 73M | 85M | 98M | 99M | 111M | 220M | 406M | 394M | 393M | 145M | 160M | 187M |
| Total Assets | 98M | 117M | 161M | 172M | 164M | 157M | 409M | 601M | 707M | 662M | 447M | 433M | 435M |
| Total Liabilities | 33M | 44M | 76M | 74M | 65M | 45M | 189M | 195M | 314M | 268M | 301M | 274M | 248M |
| Intangibles | 25M | 33M | 41M | 38M | 43M | 33M | 120M | 112M | 250M | 217M | 114M | 97M | 279M |
| Retained Earnings | 49M | 56M | 65M | 74M | 68M | 73M | 72M | 72M | 77M | 74M | -183M | -189M | -181M |
| Working Capital | 16M | 15M | 13M | 19M | 15M | 10.0M | 97M | 271M | 76M | 76M | 65M | -61M | 51M |
| Current Assets | 27M | 30M | 37M | 36M | 32M | 34M | 123M | 304M | 124M | 119M | 109M | 103M | 106M |
| Current Liabilities | 10M | 15M | 24M | 17M | 17M | 24M | 26M | 33M | 48M | 43M | 44M | 164M | 54M |
| Per Share Data | |||||||||||||
| EPS | 2.49 | 2.63 | 2.97 | 2.91 | -0.79 | 1.86 | 0.41 | 0.64 | 0.35 | 0.17 | -47.20 | -0.36 | 0.65 |
| Owner EPS | 2.13 | 1.14 | 2.23 | 1.86 | 3.89 | 4.20 | 1.95 | 1.98 | 0.52 | -3.36 | 0.12 | 1.67 | 4.15 |
| Book Value | 17.80 | 20.17 | 22.52 | 25.45 | 26.50 | 27.66 | 50.73 | 79.41 | 73.67 | 71.93 | 26.99 | 29.15 | 33.79 |
| Cash Flow/Share | 3.42 | 2.97 | 4.49 | 4.50 | 6.86 | 7.59 | 6.22 | 7.25 | 7.34 | 5.12 | 8.19 | 8.54 | 1.47 |
| Dividends/Share | 0.55 | 0.60 | 0.61 | 0.61 | 0.64 | 0.64 | 0.64 | 0.64 | 0.64 | 0.64 | 0.64 | 0.64 | 0.64 |
| Shares Out. | 3.6M | 3.6M | 3.8M | 3.8M | 3.7M | 4.0M | 4.3M | 5.1M | 5.3M | 5.5M | 5.4M | 5.5M | 5.5M |
| Valuation | |||||||||||||
| P/E Ratio | 33.6 | 26.2 | 30.1 | 40.6 | N/A | 122.9 | 490.0 | 371.2 | 698.8 | 973.4 | N/A | N/A | 150.9 |
| P/FCF | 26.7 | 31.5 | 36.7 | 79.8 | 22.7 | 31.4 | 34.2 | 34.6 | 37.6 | 38.6 | 14.1 | 15.3 | 14.2 |
| EV/EBIT | 26.6 | 17.4 | 23.0 | 30.9 | 257.3 | 95.4 | 117.4 | 88.8 | 303.6 | 314.0 | N/A | 42.3 | 32.1 |
| Price/Book | 4.7 | 3.4 | 4.0 | 4.6 | 5.2 | 8.3 | 4.0 | 3.0 | 3.3 | 2.3 | 4.0 | 4.1 | 2.9 |
| Price/Sales | 4.4 | 3.7 | 4.1 | 4.6 | 5.3 | 7.5 | 8.5 | 9.5 | 8.0 | 4.5 | 3.0 | 2.7 | 2.2 |
| FCF Yield | 3.7% | 3.2% | 2.7% | 1.3% | 4.4% | 3.2% | 2.9% | 2.9% | 2.7% | 2.6% | 7.1% | 6.5% | 7.0% |
| Market Cap | 302M | 251M | 336M | 455M | 521M | 920M | 871M | 1.2B | 1.3B | 905M | 585M | 652M | 539M |
| Avg. Price | 64.14 | 71.99 | 92.55 | 112.35 | 134.96 | 192.74 | 230.08 | 248.31 | 274.94 | 181.98 | 118.57 | 119.10 | 97.50 |
| Year-End Price | 83.64 | 69.02 | 89.44 | 118.27 | 138.92 | 228.68 | 200.88 | 237.59 | 244.58 | 165.48 | 108.52 | 118.87 | 97.50 |
MESA LABORATORIES INC /CO/ passes 2 of 9 quality checks, indicating weak fundamentals.
MESA LABORATORIES INC /CO/ trades at 150.0x trailing earnings, compared to its 15-year median P/E of 35.4x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 14.2x vs a median of 34.4x. The company's 5-year average gross margin is 61.9%. Total shareholder yield (dividends) is 0.7%. At current prices, the estimated annualized return to fair value is +0.6%.
MESA LABORATORIES INC /CO/ (MLAB) has a net profit margin of -0.8%. The company is currently unprofitable.
MESA LABORATORIES INC /CO/ (MLAB) generated $43 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
MESA LABORATORIES INC /CO/ (MLAB) has a debt-to-equity ratio of 1.12. This indicates moderate leverage.
MESA LABORATORIES INC /CO/ (MLAB) reported earnings per share (EPS) of $-0.36 in its most recent fiscal year.
MESA LABORATORIES INC /CO/ (MLAB) has a return on equity (ROE) of -1.3%. A negative ROE may indicate losses or negative equity.
MESA LABORATORIES INC /CO/ (MLAB) has a 5-year average gross margin of 61.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for MESA LABORATORIES INC /CO/ (MLAB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MESA LABORATORIES INC /CO/ (MLAB) has a book value per share of $29.15, based on its most recent annual SEC filing.
No recent press releases.